Anupam Rasayan to acquire Bliss GVS Pharma for ₹829 crore

Bliss GVS Pharma Limited announced that Anupam Rasayan India Limited (Acquirer) will acquire 2,77,26,848 shares, or 26.00% of the expanded voting share capital, through an open offer. The total consideration for this acquisition is ₹829.03 crore, with an offer price of ₹299.00 per share.

Reader Takeaway: Anupam Rasayan gains control; shareholders get exit option.

What just happened

Anupam Rasayan India Limited has entered into an agreement to purchase 4,58,03,024 equity shares of Bliss GVS Pharma Limited, representing 43.30% of the company's equity. This acquisition triggers a mandatory open offer as per SEBI (SAST) Regulations, through which Anupam Rasayan will acquire an additional 26.00% stake, bringing their total holding to a controlling interest and making them the new promoter.

Why this matters

This transaction signifies a change in control for Bliss GVS Pharma. The open offer at ₹299.00 per share provides an exit opportunity for existing public shareholders. Anupam Rasayan plans to support the target company's growth and may streamline operations for efficiency.

The backstory

This event is driven by Anupam Rasayan's strategic move to gain control of Bliss GVS Pharma. The open offer is a regulatory requirement following the acquisition of a significant stake.

What changes now

Upon successful completion of the open offer, Anupam Rasayan India Limited will become the promoter of Bliss GVS Pharma Limited. The acquirer intends to support the management and operations of Bliss GVS Pharma.

Risks to watch

• Regulatory conditions: The open offer's completion is contingent on fulfilling conditions outlined in the Share Purchase Agreement.
• Acceptance rates: There's a possibility of proportionate acceptance if more shares are tendered than the offer size, meaning not all tendered shares may be accepted.

Peer comparison

While specific peer financial data for FY2026 is provided, direct comparison of this acquisition's valuation metrics against active M&A in the Indian pharmaceutical sector would require further market analysis.

Context metrics (time-bound)

• Open Offer Price: ₹299.00 per share.
• Offer Size: 2,77,26,848 shares (26.00% of Expanded Voting Share Capital).
• Total Consideration: ₹829.03 crore.
• Acquirer Revenue (FY2026): ₹2,365.45 crore (Consolidated).
• Target Revenue (FY2026): ₹927.11 crore (Consolidated).
• Escrow Account Deposit: ₹160.00 crore.

What to track next

Investors should monitor the schedule of the open offer, any regulatory updates, and the final acceptance of shares. Evaluating the post-acquisition strategy and operational changes by Anupam Rasayan will be key.